|
000
| 01708nam 2200385zi 4500 |
|---|
| 001 | 9.907323 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20240103095635 |
|---|
| 006 | m o d f |
|---|
| 007 | cr mn||||||||| |
|---|
| 008 | 220126t20222022onc o f000 0 eng d |
|---|
| 020 | |a9780660417899 |
|---|
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aH164-327/2022E-PDF |
|---|
| 245 | 00|aGuidance on nitrosamine impurities in medications. |
|---|
| 264 | 1|a[Ottawa] : |bHealth Canada = Santé Canada, |c2022. |
|---|
| 264 | 4|c©2022 |
|---|
| 300 | |a1 online resource (iii, 25 pages) |
|---|
| 336 | |atext|btxt|2rdacontent |
|---|
| 337 | |acomputer|bc|2rdamedia |
|---|
| 338 | |aonline resource|bcr|2rdacarrier |
|---|
| 500 | |aCover title. |
|---|
| 500 | |a"Date Adopted: April 2022. Effective Date: April 2022." |
|---|
| 500 | |aIssued also in French under title: Lignes directrices sur les impuretés de nitrosamine dans les médicaments. |
|---|
| 520 | |a"Evaluating and managing the risks of N-nitrosamine impurities in human pharmaceutical, biological and radiopharmaceutical products"--Cover. |
|---|
| 650 | 0|aNitrosoamines|xRisk assessment|zCanada. |
|---|
| 650 | 0|aDrugs|xRisk assessment|zCanada. |
|---|
| 650 | 0|aBiologicals|xRisk assessment|zCanada. |
|---|
| 650 | 0|aRadiopharmaceuticals|xRisk assessment|zCanada. |
|---|
| 650 | 0|aPharmaceutical policy|zCanada. |
|---|
| 710 | 1 |aCanada. |bHealth Canada, |eissuing body. |
|---|
| 775 | 08|tLignes directrices sur les impuretés de nitrosamine dans les médicaments.|w(CaOODSP)9.907324 |
|---|
| 794 | |tGuidance on nitrosamine impurities in medications.|bSeptember 1, 2022|w(CaOODSP)9.914730 |
|---|
| 856 | 40|qPDF|s1.10 MB|uhttps://publications.gc.ca/collections/collection_2022/sc-hc/H164-327-2022-eng.pdf |
|---|